Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.

被引：0

作者：

Cotte, Alexia ^{[1
]}

Beniey, Michele ^{[1
]}

Haque, Takrima ^{[2
]}

Bechir, Nelly ^{[2
]}

Hubert, Audrey ^{[1
]}

Diallo, Korotoum W. ^{[1
]}

Tran-Thanh, Danh ^{[2
]}

Hassan, Saima N. ^{[1
]}

机构：

[1] Univ Montreal, Ctr Rech Univ Montreal CRCHUM, Montreal, PQ H3C 3J7, Canada

[2] Ctr Rech Univ Montreal CRCHUM, Montreal, PQ, Canada

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1066

引用

页数：2

共 50 条

[21] Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor [J].

Song, Dandan ;

He, Huan ;

Sinha, Indranil ;

Hases, Linnea ;

Yan, Feifei ;

Archer, Amena ;

Haldosen, Lars-Arne ;

Zhao, Chunyan ;

Williams, Cecilia .

CANCER LETTERS, 2021, 506 :23-34

[22] Cell Cycle Effects of Iniparib, a PARP Inhibitor, in Combination with Gemcitabine and Carboplatin in the MDA-MB-468(-) Triple-Negative Breast Cancer (TNBC) Cell Line [J].

Ossovskaya, V. ;

Lim, C-U ;

Schools, G. ;

Kalurupalle, S. ;

Roninson, I. B. ;

Broude, E. .

CANCER RESEARCH, 2010, 70

[23] FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden [J].

Joseph, Sydney C. ;

Eugin Simon, Samson ;

Bohm, Margaret S. ;

Kim, Minjeong ;

Pye, Madeline E. ;

Simmons, Boston W. ;

Graves, Dillon G. ;

Thomas-Gooch, Stacey M. ;

Tanveer, Ubaid A. ;

Holt, Jeremiah R. ;

Ponnusamy, Suriyan ;

Sipe, Laura M. ;

Hayes, D. Neil ;

Cook, Katherine L. ;

Narayanan, Ramesh ;

Pierre, Joseph F. ;

Makowski, Liza .

CANCERS, 2024, 16 (07)

[24] A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer [J].

Wiggs, Alleigh ;

Molina, Sabrina ;

Sumner, Susan J. ;

Rushing, Blake R. .

NUTRIENTS, 2022, 14 (10)

[25] Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy [J].

Chia, J. W. ;

Ang, P. ;

See, H. ;

Wong, Z. ;

Soh, L. ;

Yap, Y. ;

Wong, N. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[26] Epigenetic heterogeneity in triple-negative breast cancer. [J].

Maruyama, Reo ;

Yang, Liying ;

Kumegawa, Kohei .

MOLECULAR CANCER RESEARCH, 2018, 16 (08) :29-30

[27] Combination chemotherapy with docetaxel and carboplatin in triple-negative breast cancer: a single institution experience [J].

Kurbacher, C. M. ;

Kurbacher, J. A. ;

Braun, K. ;

Mehra, S. ;

Schweitzer, C. ;

Arenz, P. N. .

ONKOLOGIE, 2010, 33 :29-29

[28] Proteomic analysis of talazoparib resistance in triple-negative breast cancer cells [J].

Guney Eskiler, Gamze ;

Yanar, Sevinc ;

Akpinar, Gurler ;

Kasap, Murat .

JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (03)

[29] Chronobiological assessment of triple-negative breast cancer. [J].

Revazishvili, Pati ;

Tavartkiladze, Alexandre ;

Tavartkiladze, Levan ;

Sordia, Teimuraz ;

Gvajaia, Ani .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[30] Combination benefit between PARP inhibitor niraparib and angiogenesis inhibitors in PDX models of triple-negative breast cancer (TNBC). [J].

Zhou, Yinghui ;

Wang, Sarah ;

Mikule, Keith ;

Ramaswamy, Sridhar ;

Hanke, Jeffrey ;

Wang, Jing Yu .

MOLECULAR CANCER RESEARCH, 2018, 16 (08) :32-33

← 1 2 3 4 5 →